Literature DB >> 21135497

CD14+ CD163+ IL-10+ monocytes/macrophages: Pro-angiogenic and non pro-inflammatory isolation, enrichment and long-term secretion profile.

A Mayer1, S Lee, F Jung, G Grütz, A Lendlein, B Hiebl.   

Abstract

The establishment of a stable endothelial layer on a biomaterial suture is a well known strategy to achieve hemocompatibility. The endothelialisation is supported by factors as e.g. vascular endothelial growth factor (VEGF), which can be secreted by monocytes/macrophages (mo/mΦ) in an angiogenic milieu. In order to avoid detrimental inflammation triggered by these mo/mΦ, we established a protocol for the generation of alternatively activated macrophages and studied their response towards VEGF-A165. We could generate sufficient amounts of these CD14+ CD163+ IL-10+ mo/mΦ from buffy coats(8.6 ± 4.7 × 105 cells/mlbuffy coat). Furthermore, we achieved a VEGF-A165 secretion in the nanogram range. The VEGF-A165 secretion increased 2.1-fold within 14 days from 7.6 ± 2.2 to 16.1 ± 2.5ng/ml when the cells were grown with a VEGF-A165 supplemented (10ng/ml) cell culture medium. Within this time period the secretion levels of other pro-angiogenic growth factors (bFGF, PDGF-BB) and immunomodulatory cytokines (IL-10, IL-12, IL-1ra, TNFα, IFNγ) reached only the picogram range. These results suggest that angiogenically stimulated CD14+ CD163+ IL-10+ mo/mΦ might be useful as a cellular cytokine delivery system supporting endothelialisation of biomaterials without inducing pro-inflammatory effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135497     DOI: 10.3233/CH-2010-1348

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  7 in total

1.  Prior endurance exercise prevents postprandial lipaemia-induced increases in reactive oxygen species in circulating CD31+ cells.

Authors:  Nathan T Jenkins; Rian Q Landers; Sunny R Thakkar; Xiaoxuan Fan; Michael D Brown; Steven J Prior; Espen E Spangenburg; James M Hagberg
Journal:  J Physiol       Date:  2011-09-19       Impact factor: 5.182

2.  Up-regulation of CD163 expression in subpopulations of blood monocytes after kidney allograft transplantation.

Authors:  L Čurnová; K Mezerová; V Švachová; M Fialová; M Novotný; E Čečrdlová; O Viklický; I Stříž
Journal:  Physiol Res       Date:  2020-09-09       Impact factor: 1.881

3.  Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation.

Authors:  Jason A Horton; Kathryn E Hudak; Eun Joo Chung; Ayla O White; Bradley T Scroggins; Jeffrey F Burkeen; Deborah E Citrin
Journal:  Stem Cells       Date:  2013-10       Impact factor: 6.277

4.  Changes in phenotypic patterns of blood monocytes after kidney transplantation and during acute rejection.

Authors:  V Švachová; L Krupičková; M Novotný; M Fialová; K Mezerová; E Čečrdlová; V Lánská; A Slavčev; O Viklický; O Viklický; I Stříž
Journal:  Physiol Res       Date:  2021-09-10       Impact factor: 1.881

5.  Inhibition of PDGF-BB reduces alkali-induced corneal neovascularization in mice.

Authors:  Lei Chen; Hongya Wu; Chi Ren; Gaoqin Liu; Wenpeng Zhang; Weiming Liu; Peirong Lu
Journal:  Mol Med Rep       Date:  2021-02-04       Impact factor: 2.952

6.  CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation.

Authors:  Alena Sekerkova; Eva Krepsova; Eva Brabcova; Janka Slatinska; Ondrej Viklicky; Vera Lanska; Ilja Striz
Journal:  BMC Immunol       Date:  2014-02-06       Impact factor: 3.615

7.  The Intrapericardial Delivery of Extracellular Vesicles from Cardiosphere-Derived Cells Stimulates M2 Polarization during the Acute Phase of Porcine Myocardial Infarction.

Authors:  Esther López; Rebeca Blázquez; Federica Marinaro; Verónica Álvarez; Virginia Blanco; Claudia Báez; Irene González; Ana Abad; Beatriz Moreno; Francisco Miguel Sánchez-Margallo; Verónica Crisóstomo; Javier García Casado
Journal:  Stem Cell Rev Rep       Date:  2020-06       Impact factor: 5.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.